The United States will abandon vaccine patents, but there are still many problems with expanding vaccine production…
China News Service, May 6th. According to a report from the US Chinese website, the Biden government of the United States announced on the 5th that it supports abandoning the protection of intellectual property rights for the new crown vaccine in order to expand global vaccination. Some analysts say that this is an important measure for the United States to participate in international vaccine cooperation. However, some people say that vaccine patents are not the main obstacle to more vaccines in low- and middle-income countries; some people also claim that such agreements may undermine the motivation of companies to innovate.
p > According to reports, U.S. Trade Representative Katherine Tai wrote in a statement: “This is a global health crisis. The special situation of the new crown epidemic requires extraordinary measures. The government believes in the role of intellectual property protection, but To end this epidemic, support the abandonment of these protections for the new crown vaccine.”
The statement also said: “On the basis of ensuring sufficient supply of the new crown vaccine in the United States, the government will continue to increase its efforts to cooperate with the private sector and all Potential partners work together to expand vaccine production and distribution, while increasing the supply of raw materials needed to produce these vaccines.”
This week, the World Trade Organization urged member states to quickly finalize the details of an agreement and temporarily relax it. Intellectual property protection for the new crown vaccine in order to eliminate barriers to vaccine production in developing countries. The request was put forward by the representatives of India and South Africa, and in accordance with the WTO consensus principle, the unanimous consent of 164 member states must be obtained.
On the 5th local time, US President Biden confirmed that the White House will support the WTO’s proposal to exempt vaccine-related intellectual property rights. He said before Dai Qi’s statement: “Yes, I will talk about this issue later today.”
The analysis pointed out that the US statement on the 5th marked an important step taken by the Biden administration in global vaccine cooperation. As the US vaccine distribution work continued to advance, the Biden administration began to turn its attention to supporting overseas.
Previously at the G7 Leaders Online Summit in February, Biden announced that the United States will donate 4 billion in batches to the WHO-led “Vaccine Equitable Distribution Program” (COVAX) in the next two years. US dollars. Last week, under pressure from public opinion, the White House promised to send 60 million doses of AstraZeneca vaccine overseas. On May 4, the White House expressed support for the plan to send at least 10% of Pfizer vaccines produced in the United States overseas by July 4.
As the Biden administration announced the new measures, the new crown infection rate and death toll in dozens of low- and middle-income countries soared, and the supply of vaccines was far from meeting demand. Among them, India is the current global epicenter of the epidemic. In the past week, the country has an average of about 380,000 new confirmed cases of new crown every day, and the number of deaths in a single day exceeds 3,500. Nevertheless, experts still believe that the actual number of infections and deaths may be higher.
For months, infectious disease experts have been warning that allowing the virus to spread and mutate without restriction in any country will pose a threat to the world, because the emerging variants may be resistant to existing vaccines. Medicinal properties. This threat, coupled with the fundamental concern for human life, has prompted more and more people to support the abandonment of intellectual property protection for the new crown vaccine and treatment methods.
However, it was also pointed out that vaccine patents and other protective measures are not the main obstacles to the production of more vaccines in low- and middle-income countries. Some people also said that such agreements may harm the company’s motivation to innovate.